Retroscreen speaking and exhibiting at 2nd Vaccine Research Summit 2014

April 13, 2014 2:01 pm

20-21 May, Cumberland Hotel, London W1, UK

Retroscreen Virology, the global leader in human challenge model research, will be attending the 2nd ”Vaccines Research Summit” taking place in London, UK, 20-21st May 2014.

The summit is focused on improving strategies for innovation and scientific advancement in vaccine research. This is the second annual conference in the series and is attracting some very strong speakers including representatives from Merck Millipore, The University of Wolverhampton, Immudex, Crucell, The Centre for Medical Innovation, Infonetica, The University of Kent, Medimmune, Public Health England, S-Target Therapeutics, Leukocare and, of course, Retroscreen.

Dr Anthony Lockett, Retroscreen Senior Medical Director, will be speaking at the conference on day one, presenting “Fast track development of manufacturing processes for recombinant vaccine proteins produced using microbial systems.” Dr Lockett’s presentation will cover topics including the rapid selection of an optimal expression system and early definition of the upstream production process, exploiting pre-optimised platform approaches to purification to quickly define and establish the manufacturing process for bulk API, and reducing time-lines to move to clinical development.

In addition, Dr Lockett will be delighted to discuss all aspects of Retroscreen’s service provision and its pioneering approach to early phase clinical research with regard to human viral challenge studies in flu, RSV and rhinovirus. He will be joined during the two-day Summit by Mike Lawson, Business Development Director at Retroscreen.

Dr Lockett commented: “This event is a fantastic forum for sharing knowledge on the many facets of vaccine research. With the development of successful new drugs and vaccines slowing in recent years, Retroscreen have some excellent experience in helping to accelerate vaccine and new candidate drug development through pioneering clinical research based on our hVIVO human challenge models.”

Should you wish to make contact with Dr Lockett or Mike Lawson before or whilst attending the event please make contact by emailing either or

Comments are closed here.